CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
Ceribell, Inc. (CBLL) director Josef Parvizi reported that the Innovation ACP Trust sold 25,000 common shares on November 16, 2026, at a weighted average price of $26.02 per share. The shares were sold in multiple transactions at prices ranging from $25.60 to $26.41. The sale was made under a Rule 10b5-1 trading plan adopted August 12, 2026. Afterward, the Innovation ACP Trust held 882,911 shares. Parvizi also reported 23,284 shares held directly, 707,206 through the Josef Parvizi Trust, and 369,088 through the ACP 2021 Trust. He disclaimed beneficial ownership of the trust-held securities except to the extent of his pecuniary interest.
Ceribell, Inc. (CBLL) is the subject of a beneficial-ownership report by TPG GP A, LLC, James G. Coulter and Jon Winkelried. Each reports shared voting and dispositive power over the same 1,180,226 common shares, equal to 3.0% of the class; the reports list no sole voting or dispositive power.
The shares are directly held by The Rise Fund Clearthought, L.P. Coulter and Winkelried may be deemed to beneficially own the shares through their relationship to TPG GP A, but disclaim beneficial ownership except to the extent of their pecuniary interest. The 3.0% figure uses 38,835,010 shares outstanding as of October 30, 2026.
Ceribell, Inc. (CBLL) director Josef Parvizi gave notice of a proposed sale of 25,000 common shares, with an aggregate market value of $652,250.00 and an approximate sale date of November 16, 2026. The notice identifies the Innovation Acp Trust account for the sale and states that Parvizi is a trustee and account stakeholder. It lists August 12, 2026 as the date for plan adoption or instruction under Rule 10b5-1. The shares were acquired from Ceribell as pre-IPO shares on August 29, 2014.
Ceribell, Inc. director Josef Parvizi is named as the person for whose account 25,000 common shares are to be sold, with an approximate sale date of November 16, 2026. The remarks associate the sale with the Innovation ACP Trust account, where Josef Parvizi is a trustee and account stakeholder. The form records August 12, 2026 as the date of plan adoption or instruction under Rule 10b5-1.
Ceribell, Inc. (CBLL) director William W. Burke exercised options for 18,000 common shares on November 12, 2026, at an exercise price of $4.70 per share. He sold 16,845 shares at a weighted average of $26.58 and 1,155 shares at a weighted average of $27.48. The option position was reported as 7,151 shares after the transaction. The transactions were made under a Rule 10b5-1 trading plan.
Ceribell, Inc. (CBLL) director William W. Burke reported a proposed sale of 18,000 common shares, with an approximate sale date of November 12, 2026. The notice lists the shares as acquired from the issuer through a cash-paid stock option exercise on November 12, 2026. It also lists August 12, 2026 as the plan-adoption or instruction date if relying on Rule 10b5-1.
Ceribell, Inc. director Joseph Michael Taylor sold 10,200 shares of common stock on November 9, 2026, at a reported weighted-average price of $27.22 per share. The shares were sold in multiple transactions at prices ranging from $27.15 to $27.32 per share. Taylor directly held 38,278 shares after the sale. No Rule 10b5-1 plan is reported for the sale.
Joseph Michael Taylor, a director of Ceribell, Inc. (CBLL), gave notice of a proposed sale of 10,200 common shares, with an aggregate market value of $272,850 and an approximate sale date of November 9, 2026. Sanford C. Bernstein & Co., LLC is named as broker, and the notice says it is acting as filing agent for Taylor.
The notice lists 38,840,000 common shares outstanding. It also reports that Taylor sold 13,095 common shares on August 13, 2026, for gross proceeds of $299,613.60. The shares proposed for sale were acquired on June 28, 2017, as director compensation.
On November 2, 2026, Ceribell, Inc. Chief Technology Officer Raymond Woo exercised options for 4,864 common shares at an exercise price of $3.65 per share and 23 common shares at $4.70 per share. He also reported selling 4,887 common shares at $26.96 per share. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted June 5, 2026; the options were fully vested and currently exercisable.
CeriBell, Inc. (CBLL) reported third-quarter 2026 revenue of $29.3 million, up 30% from $22.6 million a year earlier; product revenue was $22.2 million and subscription revenue was $7.1 million. Gross profit was $26.3 million, with a 90% gross margin versus 88%. Net loss was $21.4 million, compared with $13.5 million, and basic and diluted net loss per share was $(0.55) versus $(0.37). The company attributed product-revenue growth primarily to new customers and increased Wearables use, and subscription-revenue growth primarily to new customers.
For the first nine months of 2026, revenue was $83.9 million, up 31%, and net loss was $60.4 million, compared with $39.9 million. Net cash used in operating activities was $45.2 million versus $30.0 million. As of September 30, 2026, cash, cash equivalents and marketable securities totaled $117.5 million; management believes these resources, together with expected customer receipts, will fund planned operating expenses and capital expenditures for at least the next 12 months. A $20.0 million draw on the MidCap revolving facility made September 21 was outstanding at quarter-end and was repaid October 7, 2026; no term loans were outstanding on September 30.